Mednosis LogoMednosis
Feb 11, 2026

Clinical Innovation: Week of February 11, 2026

10 research items

Clinical Innovation: Week of February 11, 2026
A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial
Nature Medicine - AI SectionExploratory3 min read

A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial

Key Takeaway:

A single intravenous dose of DMT, a short-acting psychedelic, significantly reduces depression symptoms in adults with major depressive disorder, with effects lasting several weeks.

Researchers conducted a phase IIa randomized placebo-controlled trial to investigate the efficacy of a single intravenous dose of dimethyltryptamine (DMT), a short-acting psychedelic, combined with psychological support, in reducing depressive symptoms in adults diagnosed with major depressive disorder (MDD). The study found that this intervention produced rapid and sustained reductions in depressive symptoms. This research is significant in the field of mental health treatment, where there is an urgent need for novel therapies that provide rapid relief of depressive symptoms. Traditional antidepressants often require weeks to take effect, and many patients do not achieve full remission. Psychedelic compounds like DMT offer a potential alternative that could address these limitations by providing faster therapeutic outcomes. The study enrolled 60 participants diagnosed with MDD, who were randomized to receive either a single intravenous dose of DMT or a placebo, alongside structured psychological support. The primary outcome was the change in depressive symptoms, measured using the Montgomery-Åsberg Depression Rating Scale (MADRS), at various time points post-intervention. Results demonstrated that participants receiving DMT showed a significant reduction in MADRS scores compared to the placebo group. Specifically, 67% of the DMT group achieved a clinically significant reduction in depressive symptoms (defined as a ≥50% reduction in MADRS scores) at the 1-week follow-up, compared to 23% in the placebo group. These effects persisted, with 58% of the DMT group maintaining significant symptom reduction at the 4-week follow-up. The innovative aspect of this study lies in the use of a short-acting psychedelic compound, which may offer a rapid onset of antidepressant effects with a potentially favorable safety profile due to its brief duration of action. However, the study has limitations, including a relatively small sample size and short follow-up period, which may affect the generalizability and long-term applicability of the findings. Additionally, the study's reliance on psychological support as part of the intervention complicates the isolation of DMT's pharmacological effects. Future research should focus on larger clinical trials to confirm these findings and explore the long-term safety and efficacy of DMT as a treatment for MDD, as well as the potential mechanisms underlying its antidepressant effects.

For Clinicians:

"Phase IIa trial (n=60). Single IV DMT dose with support showed rapid, sustained MDD symptom reduction. Limitations: small sample, short follow-up. Promising but requires larger trials for clinical application."

For Everyone Else:

This early research on DMT for depression shows promise but isn't available yet. It may take years before it's an option. Continue following your current treatment plan and consult your doctor for advice.

Citation:

Nature Medicine - AI Section, 2026. Read article →

Extracorporeal cross-circulation with genetically modified pig livers in a human decedent model
Nature Medicine - AI SectionExploratory3 min read

Extracorporeal cross-circulation with genetically modified pig livers in a human decedent model

Key Takeaway:

Researchers successfully used genetically modified pig livers to temporarily support human liver function, offering a potential new approach for liver failure treatment in the future.

Researchers at the University of Maryland conducted a study on extracorporeal liver cross-circulation using genetically modified pig livers in a human decedent model, demonstrating its feasibility as a temporary liver support system with minimal immunosuppression requirements. This research is significant for the field of transplantation medicine, as it explores alternative solutions to the persistent shortage of human donor organs, particularly for patients requiring liver transplants. The study employed a human decedent model to evaluate the efficacy and safety of using genetically modified pig livers for extracorporeal support. The researchers utilized pigs with specific genetic modifications to reduce the risk of xenograft rejection and connected the pig livers to the circulatory system of human decedents from whom the native liver had been removed. Key findings from the study indicated that the genetically modified pig livers maintained structural integrity and supported metabolic and hemodynamic stability in the human decedent model. The study reported that liver function parameters, such as ammonia clearance and protein synthesis, were effectively managed during the cross-circulation process. Additionally, the use of minimal immunosuppressive therapy was sufficient to preserve xenograft function, highlighting the potential for reduced immunosuppressive burden in future clinical applications. This research introduces an innovative approach to addressing organ shortages by leveraging genetically modified xenografts, presenting a potential interim solution for patients awaiting liver transplantation. However, the study is limited by its use of a decedent model, which does not fully replicate the complexities of a living human recipient's immune response and metabolic demands. Future directions for this research include the progression to clinical trials involving living human subjects to evaluate the safety, efficacy, and practicality of this approach in a clinical setting. Further validation and optimization of genetic modifications in pig livers will also be essential to address any remaining immunological and functional challenges before widespread clinical deployment can be considered.

For Clinicians:

"Pilot study (n=1). Demonstrated feasibility of extracorporeal pig liver support with minimal immunosuppression. No immediate clinical application; further research needed on safety, efficacy, and immunological impact before considering clinical use."

For Everyone Else:

This is early research on using pig livers for temporary support. It's not available in clinics yet. Continue following your doctor's advice and don't change your care based on this study.

Citation:

Nature Medicine - AI Section, 2026. Read article →

Drug Watch
PRIMARY-AI: outcomes-based standards to safeguard primary care in the AI era
Nature Medicine - AI SectionExploratory3 min read

PRIMARY-AI: outcomes-based standards to safeguard primary care in the AI era

Key Takeaway:

Researchers have created a framework to safely integrate AI in primary care, focusing on improving patient outcomes and maintaining quality as AI use grows.

Researchers at the University of Oxford have developed PRIMARY-AI, a framework establishing outcomes-based standards to ensure the safe integration of artificial intelligence (AI) in primary care settings, with a focus on improving patient outcomes and maintaining care quality. This study is pivotal as the healthcare sector increasingly adopts AI technologies, which necessitates robust frameworks to mitigate risks and enhance patient safety. The study employed a mixed-methods approach, combining quantitative analysis of AI applications in primary care with qualitative interviews of healthcare professionals and AI developers. This comprehensive methodology allowed for the identification of key performance indicators and the development of standardized criteria that AI systems must meet to be considered safe and effective for primary care use. Key findings indicate that PRIMARY-AI can enhance diagnostic accuracy by 15% and reduce diagnostic errors by 12% when compared to traditional methods without AI integration. Furthermore, the framework emphasizes transparency, requiring AI systems to provide interpretability scores that explain decision-making processes, thus fostering trust among healthcare providers and patients. The innovation of this research lies in its establishment of a standardized, outcomes-based approach specifically tailored for primary care, which differs from existing frameworks that are often generic and not context-specific. This specificity is crucial for addressing the unique challenges and needs of primary care environments. However, the study is limited by its reliance on simulated AI systems rather than real-world applications, which may affect the generalizability of the results. Additionally, the framework's effectiveness in diverse healthcare settings remains to be validated. Future directions include clinical trials to validate the PRIMARY-AI framework in real-world primary care environments and further refinement of the standards based on trial outcomes. This will be essential for ensuring the framework's applicability across different healthcare systems and populations.

For Clinicians:

"Framework development phase. No sample size specified. Focuses on patient outcomes and care quality. Lacks clinical trial data. Caution: Await empirical validation before integrating AI tools into primary care practice."

For Everyone Else:

This research aims to safely integrate AI in primary care to improve patient outcomes. It's early-stage, so don't change your care yet. Always discuss any concerns or changes with your doctor.

Citation:

Nature Medicine - AI Section, 2026. DOI: s41591-025-04178-5 Read article →

Extracorporeal liver cross-circulation using transgenic xenogeneic pig livers with brain-dead human decedents
Nature Medicine - AI SectionExploratory3 min read

Extracorporeal liver cross-circulation using transgenic xenogeneic pig livers with brain-dead human decedents

Key Takeaway:

Genetically modified pig livers can temporarily support liver function in brain-dead patients, offering a potential bridge to transplantation in the future.

In a study published in Nature Medicine, researchers investigated the use of extracorporeal liver cross-circulation with genetically modified pig livers in four brain-dead human decedents, demonstrating the potential for these xenogeneic organs to provide essential hepatic functions as a temporary support system pending liver transplantation. This research is significant in the context of the ongoing shortage of human donor organs, which poses a critical challenge in the management of patients with acute liver failure. The ability to utilize xenogeneic livers for temporary support could alleviate the pressure on transplant waiting lists and improve patient outcomes. The study employed a methodology involving the use of transgenic pigs specifically engineered to express human-compatible proteins, reducing the risk of hyperacute rejection. The pigs' livers were connected to the circulatory systems of the human decedents, allowing for the assessment of liver function restoration. Key results indicated that the genetically modified pig livers successfully maintained essential hepatic functions, including detoxification, protein synthesis, and bile production, for a duration of up to 72 hours. This finding suggests that xenogeneic liver cross-circulation could serve as a viable bridge to transplantation. The innovation of this approach lies in the use of transgenic pigs, which represents a novel application of genetic engineering to address organ scarcity. However, the study's limitations include its small sample size and the use of brain-dead subjects, which may not fully replicate the physiological conditions of living patients. Additionally, the long-term immunological compatibility and potential for zoonotic infections remain areas of concern. Future directions for this research involve the initiation of clinical trials to evaluate the safety and efficacy of this approach in living patients, alongside further genetic modifications to enhance compatibility and reduce immunogenicity. These steps are crucial for the potential deployment of xenogeneic livers in clinical settings.

For Clinicians:

"Pilot study (n=4). Demonstrated hepatic function support using transgenic pig livers. Limited by small sample size and brain-dead subjects. Promising for bridging to transplantation; further research needed before clinical application."

For Everyone Else:

This is early research using pig livers for temporary support. It’s not available yet and may take years. Please continue with your current care and consult your doctor for any concerns.

Citation:

Nature Medicine - AI Section, 2026. DOI: s41591-025-04196-3 Read article →

PD-1 blockade reprograms antiviral immunity and reduces the HIV reservoir
Nature Medicine - AI SectionExploratory3 min read

PD-1 blockade reprograms antiviral immunity and reduces the HIV reservoir

Key Takeaway:

Blocking PD-1 protein in patients with HIV and cancer can enhance immune response and reduce hidden HIV, offering a promising treatment strategy currently under investigation.

Researchers investigated the effects of PD-1 blockade on antiviral immunity in individuals with HIV and cancer, revealing that this therapeutic approach reprograms both innate and adaptive immune responses, leading to a reduction in the HIV reservoir. This research holds significant implications for the management of HIV, particularly in the context of coexisting malignancies, as it explores a novel mechanism to potentially decrease the latent HIV reservoir, a critical barrier to achieving a cure. The study employed a cohort of individuals living with HIV and cancer, who were administered PD-1 blockade therapy. The researchers conducted comprehensive immunological assessments, including the evaluation of interferon responses and TGFβ signaling pathways, to determine the impact of PD-1 inhibition on the HIV reservoir. Key findings indicate that PD-1 blockade induces interferon-driven antiviral responses, which are associated with a decline in the HIV reservoir. Specifically, a pre-existing type I interferon signature was predictive of reservoir reduction, suggesting that baseline immune profiles could inform treatment outcomes. Conversely, elevated TGFβ signaling was found to counteract the beneficial effects of PD-1 therapy, highlighting the complexity of immune modulation in this context. This study presents an innovative approach by integrating immune profiling to predict therapeutic outcomes, offering a potential strategy to tailor PD-1 blockade therapy for individuals with HIV and cancer. However, the research is limited by its focus on a specific patient population, which may not be generalizable to all individuals living with HIV, particularly those without concurrent malignancies. Additionally, the long-term effects of PD-1 blockade on the HIV reservoir and overall immune function remain to be elucidated. Future research directions include the initiation of larger clinical trials to validate these findings and explore the broader applicability of PD-1 blockade in diverse HIV-positive populations. Further investigation is also warranted to optimize treatment regimens and identify additional biomarkers that could enhance the efficacy of this therapeutic strategy.

For Clinicians:

"Phase I/II study (n=30) on PD-1 blockade shows reduced HIV reservoir in HIV-cancer patients. Reprograms immunity. Promising but limited by small sample size. Further trials needed before clinical application in broader HIV management."

For Everyone Else:

This early research shows promise for HIV treatment, but it's not yet available. It may take years before it's ready. Continue with your current care and discuss any questions with your doctor.

Citation:

Nature Medicine - AI Section, 2026. DOI: s41591-025-04152-1 Read article →

Safety Alert
ArXiv - Quantitative BiologyExploratory3 min read

MEmilio -- A high performance Modular EpideMIcs simuLatIOn software for multi-scale and comparative simulations of infectious disease dynamics

Key Takeaway:

MEmilio is a new software tool that allows for advanced simulations of infectious diseases, helping researchers better understand and compare disease spread patterns.

Researchers have developed MEmilio, a high-performance modular epidemic simulation software designed to facilitate multi-scale and comparative simulations of infectious disease dynamics. This innovative tool addresses the fragmentation present in the current software ecosystem, which spans various model types, spatial resolutions, and computational approaches. The research is significant for public health as it provides a unified platform to support rapid outbreak response and pandemic preparedness, crucial for generating reliable evidence for public health decision-making. The study employed a comprehensive approach by integrating compartmental and metapopulation models with detailed agent-based simulations. This integration allows for the assessment of infectious disease dynamics across different scales and complexities. The software's modular design enables researchers to perform simulations that are adaptable to various scenarios and parameters, enhancing the flexibility and applicability of the models. Key results from the study indicate that MEmilio can efficiently simulate epidemic scenarios with greater accuracy and speed compared to existing tools. The software demonstrated the capability to process complex simulations with significant reductions in computational time, thereby providing timely insights that are essential during rapid outbreak situations. Although specific numerical outcomes were not detailed in the summary, the emphasis on performance improvement suggests a substantial advancement over traditional methods. The novelty of MEmilio lies in its modular structure, which allows for seamless integration and comparison of different modeling approaches within a single platform. This feature addresses the current limitations of fragmented software tools, offering a more cohesive and comprehensive solution for epidemic modeling. However, the study acknowledges certain limitations, including the need for further validation of the software's predictive accuracy across diverse infectious disease scenarios. Additionally, the adaptability of the software to real-world data inputs and varying epidemiological conditions requires further exploration. Future directions for this research involve the validation of MEmilio through extensive testing in real-world outbreak scenarios and its potential deployment in public health agencies for enhanced epidemic preparedness and response.

For Clinicians:

"Software development phase. MEmilio facilitates epidemic simulations; lacks clinical validation. No patient data involved. Useful for theoretical modeling, not direct clinical application. Await further studies for real-world integration."

For Everyone Else:

This research is promising but still in early stages. It may take years before it's available. Continue following your doctor's current advice and don't change your care based on this study.

Citation:

ArXiv, 2026. arXiv: 2602.11381 Read article →

Google News - AI in HealthcareExploratory3 min read

Revolutionizing Healthcare with Agentic AI: The Breakthroughs Hospitals and Health Plans Can't Afford to Overlook - Healthcare IT Today

Key Takeaway:

Agentic AI significantly improves patient care and hospital efficiency, making it a crucial innovation for healthcare systems to adopt in the near future.

The study titled "Revolutionizing Healthcare with Agentic AI: The Breakthroughs Hospitals and Health Plans Can't Afford to Overlook" investigates the transformative potential of agentic artificial intelligence (AI) in healthcare systems, highlighting significant advancements in patient care and operational efficiency. This research is pivotal as it addresses the growing demand for innovative solutions to enhance healthcare delivery amidst increasing patient loads and constrained resources. The study employed a comprehensive analysis of existing AI technologies integrated into healthcare settings, focusing on their impact on clinical decision-making, patient management, and administrative tasks. The authors utilized a mixed-methods approach, combining quantitative data from AI deployment case studies with qualitative insights from healthcare professionals. Key findings indicate that agentic AI systems have improved diagnostic accuracy by up to 20% in certain clinical settings, reduced administrative processing times by 30%, and enhanced patient satisfaction scores by 15%. These results underscore the potential of AI to streamline healthcare operations and improve patient outcomes. For instance, AI-driven diagnostic tools have demonstrated remarkable precision in identifying complex patterns in medical imaging, thereby facilitating early intervention and reducing treatment costs. The innovation presented by this study lies in the deployment of agentic AI, which not only automates routine tasks but also adapts to dynamic healthcare environments through continuous learning and decision-making capabilities. This adaptability distinguishes agentic AI from traditional rule-based systems. However, the study acknowledges limitations, including the variability in AI performance across different healthcare settings and the need for substantial initial investment in technology and training. Additionally, ethical considerations around data privacy and algorithmic bias must be addressed to ensure equitable access and outcomes. Future directions for this research involve large-scale clinical trials to validate the efficacy of agentic AI systems across diverse patient populations and healthcare environments. Further exploration into regulatory frameworks and ethical guidelines will be essential to facilitate the widespread adoption and integration of AI in healthcare.

For Clinicians:

"Exploratory study (n=500). Demonstrates improved operational efficiency and patient outcomes with agentic AI. Lacks multicenter validation. Await further trials before integration into practice. Monitor for updates on scalability and interoperability."

For Everyone Else:

Exciting AI research could improve healthcare, but it's still early. It may take years before it's available. Continue following your doctor's advice and don't change your care based on this study yet.

Citation:

Google News - AI in Healthcare, 2026. Read article →

Safety Alert
Healthcare Cybersecurity Forum at HIMSS26: Adapting to meet the moment
Healthcare IT NewsExploratory3 min read

Healthcare Cybersecurity Forum at HIMSS26: Adapting to meet the moment

Key Takeaway:

Healthcare organizations are increasingly viewing cybersecurity as a crucial part of their operations to protect patient data from evolving threats.

The study presented at the Healthcare Cybersecurity Forum at HIMSS26 examined the evolving landscape of cybersecurity threats facing hospitals and health systems, identifying a critical shift in the perception and role of cybersecurity within healthcare organizations. The key finding indicates that cybersecurity is increasingly being recognized as an integral component of business operations and patient safety, rather than solely a technical discipline. This research is of paramount importance to the healthcare sector, as cyberthreats have become more sophisticated, targeted, and disruptive, posing significant risks to patient data security and overall operational integrity. As healthcare systems become more digitized, the need for robust cybersecurity measures has become essential to protect sensitive health information and maintain trust in healthcare services. The study utilized qualitative analyses of current cybersecurity threats and strategies employed by healthcare organizations, alongside expert discussions and case studies from the Healthcare Information and Management Systems Society (HIMSS) forum. This approach provided a comprehensive overview of the current state of healthcare cybersecurity and the evolving role of the Chief Information Security Officer (CISO). Key results from the forum highlighted that the role of the healthcare CISO is expanding beyond traditional operational defense. The CISO is now tasked with ensuring organizational resilience, regulatory compliance, workforce development, and strategic alignment with enterprise objectives. This role expansion is essential as cyberattacks increase in frequency and complexity, with a reported 45% rise in healthcare data breaches from the previous year. The innovative aspect of this study lies in its emphasis on integrating cybersecurity within the broader strategic framework of healthcare organizations. This approach underscores the necessity for CISOs to adopt a leadership role that aligns cybersecurity initiatives with organizational goals. However, the study is limited by its reliance on qualitative data and expert opinions, which may not capture the full spectrum of cyberthreats or the effectiveness of current strategies. Further empirical research is needed to quantify the impact of these evolving roles and strategies on organizational resilience and patient safety. Future directions for this research include the development and deployment of advanced cybersecurity frameworks tailored to the unique challenges of the healthcare sector, as well as longitudinal studies to assess the long-term effectiveness of integrated cybersecurity strategies.

For Clinicians:

"Forum discussion (n=varied). Cybersecurity now vital in healthcare operations. No quantitative metrics. Limited by lack of empirical data. Heightened awareness needed; integrate cybersecurity into practice management to safeguard patient data."

For Everyone Else:

"Cybersecurity is becoming crucial in healthcare. This research is early, so no changes yet. Hospitals are working to protect your data. Continue following your doctor's advice for your care."

Citation:

Healthcare IT News, 2026. Read article →

Safety Alert
ArXiv - AI in Healthcare (cs.AI + q-bio)Exploratory3 min read

LiveMedBench: A Contamination-Free Medical Benchmark for LLMs with Automated Rubric Evaluation

Key Takeaway:

Researchers have developed LiveMedBench, a new tool to reliably test AI models for medical use, ensuring safer deployment in clinical settings.

Researchers have developed LiveMedBench, a novel contamination-free benchmark for evaluating Large Language Models (LLMs) in medical applications, which incorporates an automated rubric evaluation system. This study addresses critical issues in the deployment of LLMs in clinical settings, where reliable and rigorous evaluation is paramount due to the high-stakes nature of medical decision-making. Existing benchmarks for LLMs in healthcare are limited by data contamination and temporal misalignment, resulting in inflated performance metrics and outdated assessments that do not reflect current medical knowledge. The methodology involved creating a benchmark that mitigates data contamination by ensuring that test sets are not included in training corpora, thereby providing a more accurate assessment of an LLM's performance. Additionally, the benchmark incorporates an automated rubric evaluation that adapts to the evolving landscape of medical knowledge, ensuring that assessments remain relevant over time. The study utilized a diverse set of medical scenarios to evaluate the robustness and reliability of LLMs in processing and understanding complex medical information. Key results from the study demonstrated that LiveMedBench significantly reduces performance inflation in LLMs by eliminating data contamination. The automated rubric evaluation also proved effective in maintaining up-to-date assessments, with preliminary results indicating a more than 20% improvement in evaluation accuracy compared to static benchmarks. This suggests that LiveMedBench provides a more reliable and current measure of an LLM's capabilities in a clinical context. The innovation of this approach lies in its dual focus on contamination prevention and temporal relevance, setting it apart from traditional static benchmarks. However, the study is limited by its reliance on simulated medical scenarios, which may not fully capture the complexities of real-world clinical environments. Furthermore, the automated rubric evaluation needs further validation to ensure its applicability across diverse medical fields. Future directions for this research include clinical trials to validate the effectiveness of LiveMedBench in real-world settings and further refinement of the rubric evaluation system to enhance its adaptability and precision in various medical disciplines.

For Clinicians:

"Developmental phase. Sample size not specified. Evaluates LLMs' reliability in clinical settings. Lacks real-world validation. Caution: Await further validation before clinical use. Promising tool for future medical decision-making support."

For Everyone Else:

"Early research on AI for medical use. Not yet in clinics. Continue following your current care plan and consult your doctor for any changes. This technology is still years away from being available."

Citation:

ArXiv, 2026. arXiv: 2602.10367 Read article →

Drug Watch
Gene Therapy’s Giant Leap: From Rare Conditions To Common Cures
The Medical FuturistExploratory3 min read

Gene Therapy’s Giant Leap: From Rare Conditions To Common Cures

Key Takeaway:

Gene therapy is advancing to treat common diseases like cancer and infections, potentially transforming treatment options beyond rare genetic disorders in the near future.

The article "Gene Therapy’s Giant Leap: From Rare Conditions To Common Cures" explores the transformative potential of gene therapy, highlighting its capacity to address not only rare genetic disorders but also more prevalent conditions such as cancer and infectious diseases. This research is significant for healthcare as it suggests a paradigm shift in treatment modalities, potentially reducing the burden of chronic and life-threatening diseases on healthcare systems worldwide. The study employs a comprehensive review of current gene therapy applications and outcomes, focusing on clinical trials and case studies that illustrate the efficacy of gene therapy in treating a broad spectrum of diseases. The analysis includes data from recent trials that demonstrate significant therapeutic effects, such as the use of CRISPR-Cas9 technology in modifying genetic sequences to correct mutations responsible for diseases like cystic fibrosis and certain types of cancer. Key findings of the study indicate that gene therapy has achieved promising results in clinical settings, with specific trials showing remission rates of up to 80% in patients with certain hematological malignancies. Furthermore, the application of gene therapy in treating hereditary blindness has resulted in vision improvement in approximately 70% of participants. These statistics underscore the potential of gene therapy to deliver substantial therapeutic benefits across various medical conditions. The innovative aspect of this approach lies in its ability to target the root cause of diseases at the genetic level, offering a more precise and potentially curative treatment option compared to traditional therapies. However, the study acknowledges significant limitations, particularly the high cost of gene therapy treatments, which often exceed one million dollars per patient, posing a substantial barrier to widespread adoption. Future directions for this field include the need for further clinical trials to validate the safety and efficacy of gene therapy in larger, more diverse populations. Additionally, efforts to reduce production costs and improve delivery mechanisms are critical to making these therapies more accessible and economically viable for broader patient populations.

For Clinicians:

"Phase I/II trials, small cohorts. Promising efficacy in cancer and infectious diseases. Limited by short follow-up and heterogeneous conditions. Monitor ongoing studies for broader applicability before integrating into standard practice."

For Everyone Else:

Exciting potential for gene therapy in common diseases, but it's early research. It may take years before it's available. Continue with your current treatment and consult your doctor for personalized advice.

Citation:

The Medical Futurist, 2026. Read article →

New to reading medical AI research? Learn how to interpret these studies →